Amneal Pharmaceuticals
AMRX
21.12
-0.27
-1.26%
Amneal Pharmaceuticals
US · AMRX
#1854 by market cap
Listed 1970
21.12
-0.27
-1.26%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 29 in the most recent period (2026/Q3).
- Total institutional ownership fell 3.0 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 49.62% -2.97pp
- Institutions
- 410 +29
- As of
- 2026/Q3 vs. prior period
Holder types
Individual/Insider38.18%
Mutual Fund35.77%
Hedge Fund5.76%
VC/PE Fund3.54%
Public Company2.17%
Government Pension Fund1.06%
Insurance Company0.61%
Private Company0.48%
Other12.36%
Top holders as of 2026-08-10
Tushar Patel
17.61% · 61.34M sh
BlackRock
7.71% · 26.88M sh
Akram Mahesh
5.90% · 20.56M sh
Dipan Patel
4.85% · 16.90M sh
Chirag Patel
4.53% · 15.79M sh
Chintu Patel
3.81% · 13.26M sh
Vanguard Portfolio Management, LLC
3.55% · 12.37M sh
TPG Capital, L.P.
3.54% · 12.33M sh
Rubric Capital Management LP
2.92% · 10.17M sh
Vanguard Capital Management, LLC
2.29% · 7.99M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 35 buys · 15 sells
| Name | Role | Stake |
|---|---|---|
| Tushar Patel | -- | 17.61% |
| Chirag Patel | Co-Founder, Co-CEO, President & Director | 4.53% |
| Chintu Patel | Co-Chief Executive Officer | 3.81% |
| Gautam Patel | Director | 0.55% |
| Paul Meister | Independent Chairperson | 0.24% |
| Anastasios Konidaris | Chief Financial Officer | 0.13% |
| Jeffrey George | Independent Director | 0.10% |
| Ted Nark | Independent Director | 0.09% |
| Shlomo Yanai | Independent Director | 0.09% |
| Nikita Shah | Executive Vice President | 0.07% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-16 | J. Buchi | Independent Director | Other Disposition | -20,445 | -- |
| 2026-09-10 | J. Buchi | Independent Director | Derivative Exercise and Retained | +20,445 | $14.45 |
| 2026-08-31 | Andrew Boyer | Executive VP and Chief Commercial Officer of Generics & Biosciences | Other Disposition | -80,000 | -- |
| 2026-08-20 | Andrew Boyer | Executive VP and Chief Commercial Officer of Generics & Biosciences | Other Disposition | -152,426 | -- |
| 2026-08-12 | John Kiely | Independent Director | Other Disposition | -10,000 | -- |
| 2026-08-12 | John Kiely | Independent Director | Open Market Disposition | -50,000 | $17.64 |
| 2026-08-11 | Nikita Shah | Executive Vice President | Open Market Disposition | -146,403 | $17.51 |
| 2026-08-11 | Jason Daly | Executive Vice President | Open Market Disposition | -216,613 | $17.40–17.70 |
| 2026-08-10 | J. Buchi | Independent Director | Open Market Disposition | -168,573 | $17.18 |
| 2026-08-09 | Chirag Patel | Co-Founder, Co-CEO, President & Director | Other Acquisition | +6,381,734 | -- |
| 2026-08-09 | Chintu Patel | Co-Chief Executive Officer | Other Acquisition | +6,381,734 | -- |
| 2026-08-09 | Tushar Patel | -- | Other Acquisition | +12,763,469 | -- |
| 2026-08-09 | Gautam Patel | Director | Other Acquisition | +283,632 | -- |
| 2026-05-10 | Deborah Autor | Independent Director | Open Market Disposition | -34,819 | $12.94 |
| 2026-05-06 | Paul Meister | Independent Chairperson | Derivative Exercise and Retained | +48,747 | -- |
| 2026-05-06 | J. Buchi | Independent Director | Derivative Exercise and Retained | +34,819 | -- |
| 2026-05-06 | Ted Nark | Independent Director | Derivative Exercise and Retained | +34,819 | -- |
| 2026-05-06 | Shlomo Yanai | Independent Director | Derivative Exercise and Retained | +34,819 | -- |
| 2026-05-06 | Jeffrey George | Independent Director | Derivative Exercise and Retained | +34,819 | -- |
| 2026-05-06 | Gautam Patel | Director | Derivative Exercise and Retained | +34,819 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:02:15 · For reference only, not investment advice and not tailored to your situation.
Amneal Pharmaceuticals discussion 0 comments